Funder
Medical University of Gdańsk
Polish Ministry of Science and Higher Education
Publisher
Springer Science and Business Media LLC
Subject
Health, Toxicology and Mutagenesis,Cell Biology,Toxicology
Reference42 articles.
1. Adams J, Kauffman M. Development of the proteasome inhibitor Velcade (bortezomib). Cancer Investig. 2004;22:304–11.
2. Amann VC, Ramelyte E, Thurneysen S, Pitocco R, Bentele-Jaberg N, Goldinger SM, et al. Developments in targeted therapy in melanoma. Eur J Surg Oncol. 2016:1–13.
3. Amschler K, Schön MP, Pletz N, Wallbrecht K, Erpenbeck L, Schön M. NF-kappa B inhibition through proteasome inhibition or IKKbeta blockade increases the susceptibility of melanoma cells to cytostatic treatment through distinct pathways. J Invest Dermatol. 2010;130:1073–86.
4. Berenson A, Vardanyan S, David M, Wang J, Harutyunyan NM, Gottlieb J, et al. Outcomes of multiple myeloma patients receiving bortezomib, lenalidomide, and carfilzomib. Ann Hematol. 2016 (ahead of print)
5. Bomirski A, Słominski A, Bigda J. The natural history of a family of transplantable melanomas in hamsters. Cancer Metastasis Rev. 1988;7:95–118.
Cited by
13 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献